A novel algorithm to redefine blood-based tumor mutational burden for optimized prediction of clinical benefits from immunotherapy.

被引：1
|
作者：
Wang, Zhijie
Wang, Guoqiang
Duan, Jianchun
Zhao, Jing
Zhao, Zhengyi
Bai, Hua
Wang, Shuhang
Cai, Shangli
Wang, Jie
机构：
[1] Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, State Key Lab Mol Oncol,Dept Med Oncol, Beijing, Peoples R China
[2] Peking Union Med Coll, Beijing, Peoples R China
[3] 3D Med Inc, Med Dept, Shanghai, Peoples R China
[4] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e20514
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20514
引用
收藏
页数：1
相关论文
共 45 条
  • [1] A novel algorithm to redefine blood-based tumor mutational burden for optimized prediction of clinical benefits from immunotherapy
    Wang, Zhijie
    Wang, Guoqiang
    Duan, Jianchun
    Zhao, Jing
    Zhao, Zhengyi
    Bai, Hua
    Wang, Shuhang
    Cai, Shangli
    Wang, Jie
    CANCER RESEARCH, 2019, 79 (13)
  • [2] Theoretical model and clinical validation of blood tumor mutation burden (bTMB) detection for cancer immunotherapy.
    Duan, Jianchun
    Wang, Zhijie
    Lu, Jing
    Bai, Hua
    Wan, Rui
    Wang, Shuhang
    Xu, Jiachen
    Cao, Xinkai
    Dong, Hua
    Xu, Tongfu
    Cai, Shangli
    Li, Fu-Gen
    Wang, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers
    Barnett, Reagan M.
    Jang, Albert
    Lanka, Sree
    Fu, Pingfu
    Bucheit, Leslie A.
    Babiker, Hani
    Bryce, Alan
    Meyer, Haley M.
    Choi, Yujin
    Moore, Casey
    Garje, Rohan
    Gao, Xin
    Kim, Dae Won
    Chang, Richard Y.
    Gulhati, Pat
    Ramaker, Ryne
    Bansal, Rani
    Zhang, Tian
    Oliver Sartor, A.
    Armstrong, Andrew J.
    Bilen, Mehmet A.
    Barata, Pedro
    COMMUNICATIONS MEDICINE, 2024, 4 (01):
  • [4] Blood-based tumor mutational burden from circulating tumor DNA and immune checkpoint inhibitors in advanced prostate cancer.
    Rauterkus, Grant
    Hadadi, Agreen
    Barnett, Reagan
    Weipert, Caroline
    Drusbosky, Leylah
    Gao, Xin
    Lilly, Michael B.
    Bryce, Alan Haruo
    Naqvi, Syed Arsalan Ahmed
    Barata, Pedro C.
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [5] Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC
    Schuurbiers, Milou
    Huang, Zhongyun
    Saelee, Senglor
    Javey, Manana
    de Visser, Leonie
    van den Broek, Daan
    Monkhorst, Kim
    van den Heuvel, Michel
    Lovejoy, Alexander F.
    Klass, Daniel
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (02)
  • [6] Blood-Based Tumor Mutation Burden as a Predictive Biomarker for Clinical Benefit of Immunotherapy in Small-Cell Lung Cancer
    Hu, X.
    Yuan, M.
    Feng, Y.
    Zhang, T.
    Zhang, L.
    Dong, G.
    Zhu, H.
    Liu, Y.
    Xing, P.
    Wang, H.
    Li, B.
    Shi, Y.
    Chen, R.
    Xia, X.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S495 - S495
  • [7] Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
    David R. Gandara
    Sarah M. Paul
    Marcin Kowanetz
    Erica Schleifman
    Wei Zou
    Yan Li
    Achim Rittmeyer
    Louis Fehrenbacher
    Geoff Otto
    Christine Malboeuf
    Daniel S. Lieber
    Doron Lipson
    Jacob Silterra
    Lukas Amler
    Todd Riehl
    Craig A. Cummings
    Priti S. Hegde
    Alan Sandler
    Marcus Ballinger
    David Fabrizio
    Tony Mok
    David S. Shames
    Nature Medicine, 2018, 24 : 1441 - 1448
  • [8] Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+NSCLC (POPLAR and OAK)
    Gandara, D. R.
    Kowanetz, M.
    Mok, T. S. K.
    Rittmeyer, A.
    Fehrenbacher, L.
    Fabrizio, D.
    Otto, G.
    Malboeuf, C.
    Lieber, D.
    Paul, S. M.
    Amler, L.
    Riehl, T.
    Schleifman, E.
    Cummings, C. A.
    Hegde, P. S.
    Zou, W.
    Sandler, A.
    Ballinger, M.
    Shames, D. S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
    Gandara, David R.
    Paul, Sarah M.
    Kowanetz, Marcin
    Schleifman, Erica
    Zou, Wei
    Li, Yan
    Rittmeyer, Achim
    Fehrenbacher, Louis
    Otto, Geoff
    Malboeuf, Christine
    Lieber, Daniel S.
    Lipson, Doron
    Silterra, Jacob
    Amler, Lukas
    Riehl, Todd
    Cummings, Craig A.
    Hegde, Priti S.
    Sandler, Alan
    Ballinger, Marcus
    Fabrizio, David
    Mok, Tony
    Shames, David S.
    NATURE MEDICINE, 2018, 24 (09) : 1441 - +
  • [10] A Modi fied Algorithm Adjusting Both High and Minor Allele Frequency Mutation to Rede fine Blood-Based Tumor Mutational Burden (bTMB) for Optimal Prediction of Clinical Bene fits From Immune Checkpoint Inhibitor Therapy
    Liu, Zhichao
    Xie, Zhanhong
    Cai, Xiuyu
    He, Jianxing
    Liang, Wenhua
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (05) : E69 - E72
12345